Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB/TR 209, SFB 1101, SFB/TR 261, KO-2313/6-1, KO-2313/2)
Exzellenzcluster Mikrobiologie (EXC-2124)
Bundesministerium für Bildung und Forschung (01ZX1301F, 01ZX1301A, 01ZX1601G)
Eberhard Karls Universität Tübingen
Received: 26 June 2020
Accepted: 21 January 2022
First Online: 7 February 2022
: For the illustrated use case on liver cancer, we received ethical approval by the ethical commission of the University Hospital of Tübingen.
: Not applicable.
: The authors declare that they have no competing interests.